Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Laryngoscope. 2012 Oct 11;122(12):2712–2722. doi: 10.1002/lary.23572

Figure 3.

Figure 3

Figure 3

Overall Survival (OS) and Disease-Specific Survival (DSS) associated with adjuvant therapies for lymph node positive disease were modified by number of positive lymph nodes and extracapsular spread (ECS) status. (A) Estimates of adjusted OS HR and 95% CI for adjuvant therapies by number of positive lymph nodes for ECS negative disease. (B) Adjusted OS HR estimates and 95% CI for adjuvant therapies by number of positive lymph nodes for ECS positive disease. OS models presented in (A) and (B) were adjusted for age, race, T stage and cancer site. (C) Estimates of adjusted DSS HR and 95% CI for adjuvant therapies by number of positive lymph nodes for ECS negative disease. (D) Adjusted DSS HR and 95% CI for adjuvant therapies by number of positive lymph nodes for ECS positive disease. DSS models presented in (C) and (D) were adjusted for cancer site and T stage. These analyses included only patients with lymph node positive disease.